OMS906

About Omeros

Founded in 1994, Omeros has evolved from a GPCR discovery pioneer into a commercial entity with a strategic focus on the complement system. Its key achievement is the FDA approval of OMIDRIA for cataract surgery, while its primary value drivers are the late-stage investigational drugs narsoplimab for HSCT-TMA and OMS906 for PNH. The company's strategy involves prioritizing these high-potential clinical programs, seeking regulatory approvals and partnerships, and managing its significant debt burden to achieve sustainable growth.

About Omeros

Founded in 1994, Omeros has evolved from a GPCR discovery pioneer into a commercial entity with a strategic focus on the complement system. Its key achievement is the FDA approval of OMIDRIA for cataract surgery, while its primary value drivers are the late-stage investigational drugs narsoplimab for HSCT-TMA and OMS906 for PNH. The company's strategy involves prioritizing these high-potential clinical programs, seeking regulatory approvals and partnerships, and managing its significant debt burden to achieve sustainable growth.

About Omeros

Founded in 1994, Omeros has evolved from a GPCR discovery pioneer into a commercial entity with a strategic focus on the complement system. Its key achievement is the FDA approval of OMIDRIA for cataract surgery, while its primary value drivers are the late-stage investigational drugs narsoplimab for HSCT-TMA and OMS906 for PNH. The company's strategy involves prioritizing these high-potential clinical programs, seeking regulatory approvals and partnerships, and managing its significant debt burden to achieve sustainable growth.

About Omeros Corporation

Omeros Corporation is a Seattle-based biopharma company with a 30-year history focused on discovering and commercializing first-in-class therapeutics for large-market and orphan indications. The company achieved a pivotal transition to commercial operations with the 2014 FDA approval of OMIDRIA® for cataract surgery and is now advancing a deep pipeline anchored by its novel lectin pathway complement inhibitor, narsoplimab, targeting severe conditions like hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Omeros's strategy combines revenue generation from its commercial asset with targeted R&D investments in its proprietary GPCR and immunology platforms to address high-value, underserved medical markets.

Therapeutic Areas

Other Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs